ES2529369B2 - Use of the compound 2,5-calcium dihydroxybenzenesulfonate (calcium dobesilate) for the preparation of a medicine for the treatment of achondroplasia - Google Patents

Use of the compound 2,5-calcium dihydroxybenzenesulfonate (calcium dobesilate) for the preparation of a medicine for the treatment of achondroplasia Download PDF

Info

Publication number
ES2529369B2
ES2529369B2 ES201300662A ES201300662A ES2529369B2 ES 2529369 B2 ES2529369 B2 ES 2529369B2 ES 201300662 A ES201300662 A ES 201300662A ES 201300662 A ES201300662 A ES 201300662A ES 2529369 B2 ES2529369 B2 ES 2529369B2
Authority
ES
Spain
Prior art keywords
calcium
dihydroxybenzenesulfonate
achondroplasia
dobesilate
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201300662A
Other languages
Spanish (es)
Other versions
ES2529369A1 (en
Inventor
Ana CASTRO BUGARÍN
Ana Isabel GUZMÁN ARÁNGUEZ
María J. PÉREZ DE LARA
Patricia LOMA LOZANO
Alba MARTÍN GIL
Jesús Jerónimo PINTOR JUST
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OCUPHARM DIAGNOSTICS S L
OCUPHARM DIAGNOSTICS SL
Original Assignee
OCUPHARM DIAGNOSTICS S L
OCUPHARM DIAGNOSTICS SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OCUPHARM DIAGNOSTICS S L, OCUPHARM DIAGNOSTICS SL filed Critical OCUPHARM DIAGNOSTICS S L
Priority to ES201300662A priority Critical patent/ES2529369B2/en
Publication of ES2529369A1 publication Critical patent/ES2529369A1/en
Application granted granted Critical
Publication of ES2529369B2 publication Critical patent/ES2529369B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención describe la aplicación del 2,5-dihidroxibencenosulfonato de calcio (calcio dobesilato) para el tratamiento de la acondroplasia (enanismo). La aplicación del 2,5-dihidroxibencenosulfonato de calcio (calcio dobesilato) es capaz de reducir el nivel de fosforilación de las proteínas ERK1/2 que están anormalmente elevadas en la acondroplasia y causa los efectos característicos del enanismo. El efecto del 2,5-dihidroxibencenosulfonato de calcio (calcio dobesilato) reduciendo la fosforilación de ERK1/2 está relacionado con la disminución de los efectos patológicos asociados a esta enfermedad.The present invention describes the application of calcium 2,5-dihydroxybenzenesulfonate (calcium dobesilate) for the treatment of achondroplasia (dwarfism). The application of calcium 2,5-dihydroxybenzenesulfonate (calcium dobesilate) is able to reduce the level of phosphorylation of ERK1 / 2 proteins that are abnormally elevated in achondroplasia and cause the characteristic effects of dwarfism. The effect of calcium 2,5-dihydroxybenzenesulfonate (calcium dobesilate) reducing the phosphorylation of ERK1 / 2 is related to the decrease in the pathological effects associated with this disease.

Description

imagen1image 1

imagen2image2

imagen3image3

imagen4image4

imagen5image5

imagen6image6

imagen7image7

imagen8image8

imagen9image9

imagen10image10

imagen11image11

imagen12image12

imagen13image13

imagen14image14

imagen15image15

imagen16image16

Claims (1)

imagen1image 1 imagen2image2 imagen3image3 imagen4image4
ES201300662A 2013-07-09 2013-07-09 Use of the compound 2,5-calcium dihydroxybenzenesulfonate (calcium dobesilate) for the preparation of a medicine for the treatment of achondroplasia Expired - Fee Related ES2529369B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201300662A ES2529369B2 (en) 2013-07-09 2013-07-09 Use of the compound 2,5-calcium dihydroxybenzenesulfonate (calcium dobesilate) for the preparation of a medicine for the treatment of achondroplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201300662A ES2529369B2 (en) 2013-07-09 2013-07-09 Use of the compound 2,5-calcium dihydroxybenzenesulfonate (calcium dobesilate) for the preparation of a medicine for the treatment of achondroplasia

Publications (2)

Publication Number Publication Date
ES2529369A1 ES2529369A1 (en) 2015-02-19
ES2529369B2 true ES2529369B2 (en) 2015-10-14

Family

ID=52469462

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201300662A Expired - Fee Related ES2529369B2 (en) 2013-07-09 2013-07-09 Use of the compound 2,5-calcium dihydroxybenzenesulfonate (calcium dobesilate) for the preparation of a medicine for the treatment of achondroplasia

Country Status (1)

Country Link
ES (1) ES2529369B2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0203172B8 (en) * 2001-09-28 2021-05-25 Nakao Kazuwa pharmaceutical composition for achondroplasia
ES2286933B1 (en) * 2006-01-11 2009-10-02 Fundacion Lopez Hidalgo TREATMENT OF ACONDROPLASIA THROUGH THE ADMINISTRATION OF PIRIDOXAL AND ITS DERIVATIVES.
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
ES2315117B1 (en) * 2006-08-16 2009-12-30 Action Medicines, S.L. USE OF 2,5-DIHYDROXIBENCENIC DERIVATIVES IN THE PREPARATION OF USEFUL MEDICATIONS IN THE TREATMENT OF ASTHMA.

Also Published As

Publication number Publication date
ES2529369A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
ES2643827T3 (en) Procedure for the regulation of the thickness profile of blown films
ES2661582T3 (en) Anti-inflammatory effect of microfibrillated cellulose
ES2644468T3 (en) Synthetic transgene of methylmalonyl-CoA mutase for the treatment of methylmalonic acidemia (MMA) of MUT class
NI201500140A (en) THERAPEUTIC COMPOUNDS AND COMPOSITIONS
CO6791571A2 (en) Modulators of protein tyrosine kinase 7 (ptk7) for the diagnostic treatment or prophylaxis of neoplastic disorders
ES2421956B1 (en) NEW CRYSTAL FORM OF SITAGLIPTINA SULFATE
ES2643814T3 (en) Forklift equipped with stabilization means
CL2016001587A1 (en) Derivative based on 1,2-naphthoquinone and method of preparation thereof.
ES2596248T3 (en) N-Carbamoylputrescine to improve muscle protein synthesis
ES2542156B1 (en) Natural Aloe Vera cold gel without stabilizers
ES2641554T3 (en) Parts kit for surgical anchor placement
ES2486441B1 (en) Combined preparations of urinary acidifiers and crystallization inhibitors and their application for the treatment or prevention of phosphate or calcium phosphate-induced renal lithiasis
ES2527701B1 (en) Bone fixation device
ES2529369B2 (en) Use of the compound 2,5-calcium dihydroxybenzenesulfonate (calcium dobesilate) for the preparation of a medicine for the treatment of achondroplasia
ES2642175T3 (en) Cable
ES2644872T3 (en) Transport device for the transport of parts for the manufacture of bodies in the automotive industry
ES2644989T3 (en) Lighter Activation Mechanism
ES2536842T3 (en) Pharmaceutical composition for cancer treatment
ES2612216T3 (en) Device for fixing a roof profile
ES2533758B1 (en) Composition comprising albumin for use in the treatment of decompensated cirrhosis
ES2644800T3 (en) Package to store a product
ES2526935B2 (en) Compounds for the treatment of Leishmania infections
ES2643369T3 (en) Modified-release oral pharmaceutical formulation containing gliclazide
ES1122730U (en) Shoe with parts and replaceable floors. (Machine-translation by Google Translate, not legally binding)
ES2405259B1 (en) USE OF THE CHARMER (+) - C75 FOR THE TREATMENT OF OBESITY.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2529369

Country of ref document: ES

Kind code of ref document: B2

Effective date: 20151014

FD2A Announcement of lapse in spain

Effective date: 20211203